A Phase I/II Trial Assessing Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.

Conditions:   ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer;   a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status Interventions:   Drug: Durvalumab;   Drug: Olaparib;   Drug: Fulvestrant Sponsors:   UNICANCER;   ARCAGY- GYNECO;   SOLTI Breast Cancer Research Group Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials